Search for: "NEXUS PHARMACEUTICALS, INC." Results 41 - 58 of 58
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
25 Jul 2008, 10:51 am
Indeed, bifurcation is a common feature of pharmaceutical mass torts. [read post]
13 Sep 2007, 10:48 am
Jude Medical, Inc., 425 F.3d 1116, 1119-21 (8th Cir. 2005), and Castano v. [read post]
3 Jun 2022, 10:03 am by Robert B. Milligan
In the case, a pharmaceutical company sued a former product development employee and his new employer in the District of New Jersey for misappropriation of trade secrets in violation of the DTSA. [read post]
2 Apr 2018, 7:12 am by assoulineberlowe
A&B argued that there was a “fair nexus” between Keegan’s legal fees generated protecting Callado’s properties from foreclosure and the properties themselves. [read post]
18 May 2009, 5:24 am
: Omnicare, Inc v OHIM, Astellas Pharma GmbH (Class 46) CFI delivers judgment in case concerning ability of designer who assigns business and related IP to another company, to object when the company tries to register his name as a CTM: Elio Fiorucci v OHIM (IPKat) CFI: Good faith irrelevant when selling non-misleading sausages: Alberto Severi, in his own name and representing Cavazzuti e figli SpA, now known as Grandi Salumifici Italiani SpA v Regione Emilia-Romagna (IPKat) CFI clarifies… [read post]
18 Feb 2022, 7:37 am by Raquel Leslie, Brian Liu
The list included manufacturers in critical industries, including producers of pharmaceutical products and semiconductor parts. [read post]
1 Sep 2011, 5:10 pm by INFORRM
IMS Health Inc (23 June 2011) in which the Court voted 6-3 to strike down Vermont’s Prescription Confidentiality Law, which had prohibited the use, sale or disclosure of prescriber histories in pharmaceutical marketing to physicians. [read post]
13 Mar 2022, 9:44 am by Kevin LaCroix
On November 6, 2020, KBL entered a business combination with 180 Life Sciences Corp, Katexco Pharmaceuticals Corp., and CannBioRx. [read post]
27 Mar 2023, 9:01 pm by renholding
This figure is significantly lower than in 2016, when the Delaware Court of Chancery effectively put an end to the practice of disclosure-only settlements in In re Trulia Inc. [read post]